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Abstract
Background: This study aimed to assess the effect of cisplatin-induced toxicities on biochemical and pathological parameters such
as body, liver, and kidney weights, blood urea nitrogen (BUN), creatinine, alanine aminotransferase (ALT), and blood cells (RBCs
and WBCs) in white Swiss albino mice.
Methods: Cisplatin’s potential toxic effects on body, liver, and kidney weights were evaluated using standard laboratory methods.
Blood biochemical levels such as BUN, creatinine, and ALT levels were determined by an auto-hemolyzer using commercial
diagnostic kits. Blood cells (RBCs and WBCs) were counted under a microscope by a hemocytometer.
Results: Cisplatin’s potential toxic effects on body, liver, and kidney weights were evaluated using standard laboratory methods.
Blood biochemical levels such as BUN, creatinine, and ALT levels were determined by an auto-hemolyzer using commercial
diagnostic kits. Blood cells (RBCs and WBCs) were counted under a microscope by a hemocytometer.
Conclusions: This study suggested to increase caution when using cisplatin, particularly at high doses. Further investigation shall
be performed to minimize its toxic effect and optimize its use.
K e y w o r d s : alanine aminotransferase, biochemical parameters, blood urea nitrogen, cisplatin, mice

INTRODUCTION

initiating apoptosis and DNA damage and accelerating
inflammation on the proximal and distal convoluted
tubules of the kidney.3 In this organ, cisplatin may gather
in the proximal convoluted tubule and activate various
signaling pathways responsible for tubular cellular death.4
Cisplatin (single dose) administration exhibits toxicity in
nephrons in a considerable number of patients (around
32% to 38%).5 At post cisplatin administration, higher
platinum concentration can be found in renal tissues than
in other organs.3 According to a molecular level study,
significant expression of copper transporter receptor 1
and inorganic cation receptor 2 can accelerate the
damage of proximal tubules in S3 segment, resulting in
cisplatin transport to the kidney tubule and remarkable
platinum accumulation in renal tissues. Nephrotoxicity is
the prompt loss of kidney function and is elucidated by
the high serum concentrations of creatinine and blood
urea nitrogen (BUN) that result in kidney failure. 3

Cisplatin is an efficacious antineoplastic agent that is
widely and commonly used against several types of
cancer, such as ovarian, lung, bladder, and testicular. This
drug is used as a single dose or in combination with other
antineoplastic drugs.1 Its significant antitumor activity is
often hampered by the development of various toxic
effects. Neurotoxicity, ototoxicity, nephrotoxicity, nausea,
and vomiting are the most common toxic effects of this
drug and thus became the major limiting factors for its
use.
The most important toxic effect of cisplatin is dosedependent nephrotoxicity and hepatotoxicity.2 In general,
its efficacy is reduced due to these undesirable side
effects. This drug may induce acute nephrotoxicity by
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Although cisplatin-associated nephrotoxicity is common
in clinical and animal studies, hepatotoxicity is another
major dose-dependent adverse effect of cisplatin-based
chemotherapy6 and therefore must be considered. One
of the most important causative factors for cisplatin-
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induce hepatotoxicity is oxidative stress. Metallothionein is
one of the most important protective protein for the
treatment of cisplatin-induced liver injury. 7 Vitamin E
and selenium reduce the cisplatin-induced oxidative
damage to the liver.8, 9 Heme oxygenase and catalase
exhibit significant defensive activities against cisplatininduced liver toxicity. 10 Elevated GSH and GST levels are
an important marker for CDDP-induced hepatotoxicity.11
Many studies reported that patients treated with
platinum combinations such as cisplatin have a great
possibility of developing severe anemia. 12, 13
Cisplatin or chemotherapy combinations containing this
agent are also responsible for severe myelosuppression.
This drug induces leukocytopenia, thrombocytopenia,
and severe anemia, an unusual term to use for patients
treated with combination therapy containing cytotoxic
agents that are not only cisplatin. For hemolysis and
erythropoiesis, anemia is the secondary consideration.
However, thorough investigation has not been
conducted to determine the mechanisms. A previous
work evaluated the cisplatin effects on hemopoiesis,
especially on hemopoietic stem cells. 14
No previous single study employed different cisplatin
doses and evaluated all these parameters at a specific
time. Therefore, we designed the current research to
examine the effect of different specific doses of cisplatin
on these parameters in an experimental animal model.
MATERIALS AND METHODS
Materials
Cisplatin injection was purchased from Beacon
Pharmaceutical Ltd., Dhaka, Bangladesh. Urea,
creatinine, and ALT was provided by Randox
Laboratories Ltd., UK. Ketamine HCl (10 ml), xylazine HCl
(30 ml), 10% formalin, and distilled water were obtained
from Gonoshasthaya Pharmaceuticals Ltd., Dhaka,
Bangladesh. Reagents and other chemicals were of
analytical grade, and all dilutions were prepared using
high-purity deionized water.
Animal model and housing
Healthy female white Swiss albino mice (6–8 weeks of 18–
22 g) were purchased from the Department of
Pharmacy, Jahangirnagar University, Savar-1342,
Bangladesh and were kept in plastic (polypropylene
plastic) cages of 30 × 20 × 13 cm dimension. Soft wood
shavings were used as bedding in the cages. Animal
feeding was performed with standard laboratory pellet
diet and water at libitum, and the animals were exposed
to alternate cycle of 12 h dark and light at temperature
25 ± 2 °C and relative humidity 55% ± 10%. All the
experimental animals were allowed to adjust to the
laboratory environment for 7 days before the
experiment. Ethical approval was obtained from the
institutional animal ethical committee.
Makara J Health Res.

Experimental design
Forty-eight healthy mice were randomly selected and
divided into four groups of five (n = 5): Group 1, control
group; Group 2, mice treated with cisplatin at 10 mg/kg
body weight; Group 3, mice treated with cisplatin at 20
mg/kg body weight; and Group 4, mice treated with
cisplatin at 40 mg/kg body weight.
Cisplatin was administered intraperitoneally (i.p.) at a
single dose to the respected groups, which were then
sacrificed 6 h, 72 h, and 7 days later. Mouse initial and
final body weights were documented prior to the
treatments and before sacrifice. Body organs (kidney
and liver) and blood samples were collected to analyze
the toxic effect of cisplatin. The protocol was approved
by the institutional research committee and was
adopted in this study with minor modification.
Blood biochemical analysis
The blood samples were centrifuged for 15 min at 3000
rpm (Digisystem Laboratory instruments Inc., China,
DSC-200T). After separation, the serum was collected
carefully and stored in the refrigerator at −80 °C for
analysis. All biochemical parameters were assessed
within 24 h of sample collection using respective analysis
kits, e.g., Urea kit (CAT# CS 611, Crescent Diagnostics,
Saudi Arabia), Creatinine kit (CAT # CR510, Randox
Laboratories, UK), and ALT kit (CAT# CS 601/602, Randox
Laboratories Ltd., UK) in accordance with the
manufacturer’s instructions. BUN, creatinine, and ALT
levels were measured by a semi-automatic biochemistry
analyzer using commercial diagnostic kits (CHEM-7, Erba
Diagnostics Mannheim, Germany). 15 Blood cells (RBCs
and WBCs) were counted under a microscope by a
hemocytometer.16
Pathological examination
After the experimental animals were sacrificed, the
organs of interest were separated and preserved in
normal saline for 24 h. After being collected and dried,
each organ was weighed, and the average weights were
compared for statistical evaluation.
Statistical analysis
All data were expressed as mean ± standard error mean
(SEM). Paired t-test was performed to evaluate statistically
significant differences between experimental and
control groups (SPSS software, version 20.0). * p < 0.05,
** p < 0.01, and *** p < 0.001 were considered as
statistically significant.
Ethical approval
This study was approved by the ethical committee of
Noakhali Science and Technology University, Noakhali,
Bangladesh (Application no: 91).
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RESULTS

liver and kidney weights was observed in the high
cisplatin dose (40 mg/kg) group compared with that in
the other group. All these values are listed in Table 2.

Clinical observation
The growth function and body weight of the
experimental animal were monitored. After cisplatin
administration, the body weight of the mice depleted
remarkably (p < 0.0001) compared with that in the
control group as shown in Table 1.

Biochemical examination
Tables 3, 4, 5, and 6 show the different biochemical
parameters tested in this study. A statistically significant
increase in BUN, creatinine, and ALT levels was found in
the mice treated with cisplatin. The mice treated with 40
mg/kg cisplatin dose showed statistically significant (p <
0.05) increase in BUN, creatinine, and ALT levels
compared with the other groups including the control
group. Meanwhile, RBC and WBC counts decreased in all
the experimental groups, but this change was significant
in group 4 (p < 0.01).

Organ weight
The average kidney and liver weights of the mice
decreased in the cisplatin-treated groups (p < 0.05) than
in the control group. For different doses (10, 20, and 40
mg/kg), the average liver and kidney weights were
reduced. Statistically significant decrease in the average

TABLE 1. Changes in the body weight of the mice after 6 h, 72 h, and 1 week
Body Weight (g)
Treatment

6h

72 h

1 week

Group 1 (Control)

22.00 ± 0.58

22.89 ± 0.11

23.83 ± 0.44

% of Body Weight Changes
13.47%

Group 2 (10 mg/kg body)

22.06 ± 1.06

18.00 ± 0.10

19.00 ± 0.19

-13.87%

Group 3 (20 mg/kg body)

22.03 ± 0.22

15.00 ± 0.29

17.50 ± 0.58

-20.56%

Group 4 (40 mg/kg body)

20.00 ± 0.58

12.00 ± 0.30

16.00 ± 0.59

-20%

Values are represented as mean ± standard error mean (n = 5)

TABLE 2. Effect of cisplatin on the average kidney weight of mice
Kidney weight (g)

Treatment

6h

72 h

1 week

Group 1 (Control)

0.35 ± 0.01

0.45 ± 0.04

0.48 ± 0.02

Group 2 (10 mg/kg body)

0.39 ± 0.03

0.21 ± 0.002**

0.22 ± 0.001*

Group 3 (20 mg/kg body)

0.34 ± 0.05

0.21 ± 0.002**

0.21 ± 0.001*

Group 4 (40 mg/kg body)

0.32 ± 0.021

0.11 ± 0.002**
0.16 ± 0.030**
Values are represented as mean ± standard error mean (n = 5); *p < 0.05, **p < 0.01 versus control
TABLE 3. Effect of cisplatin on the average liver weight of mice
Treatment

Liver weight (g)
6h

72 h

1 week

Group 1 (Control)

1.294 ± 0.104

1.39 ± 0.058

1.464 ± 0.049

Group 2 (10 mg/kg body)

1.552 ± 0.102

0.612 ± 0.112**

1.188 ± 0.120*

Group 3 (20 mg/kg body)

1.438 ± 0.102

1.184 ± 0.025**

1.249 ± 0.017**

Group 4 (40 mg/kg body)

1.248 ± 0.031

0.271 ± 0.132**

0.862 ± 0.218*

Values are represented as mean ± standard error mean (n = 5); *p < 0.05, **p < 0.01 versus control

TABLE 4. Effect of cisplatin on the average liver weight of mice
Treatment

BUN (mg/dL)
6h

72 h

1 week

Group 1 (Control)

2.317 ± 0.607

24.02 ± 0.489

24.433 ± 0.361

Group 2 (10 mg/kg body)

18.403 ± 0.226***

74.613 ± 0.576***

43.393 ± 0.636***

Group 3 (20 mg/kg body)

25.367 ± 0.610**

129.447 ± 0.448***

60.603 ± 0.473***

Group 4 (40 mg/kg body)

31.04 ± 0.774***
180.91 ± 0.692***
97.583 ± 0.468***
Values are represented as mean ± SEM (n = 5); * p < 0.05, ** p < 0.01, ***p < 0.001 versus control.
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TABLE 5. Effect of cisplatin on creatinine
Treatment

Creatinine (mg/dL)
6h

72 h

1 week
0.567 ± 0.033

Group 1 (Control)

0.5 ± 0.058

0.307 ± 0.012

Group 2 (10 mg/kg body)

0.373 ± 0.037

1.5 ± 0.058***

1.4 ± 0.251**

Group 3 (20 mg/kg body)

0.667 ± 0.033

4.067 ± 0.088***

1.4 ± 0.058***

Group 4 (40 mg/kg body)

0.767 ± 0.033**

5.397 ± 0.232***

2.59 ± 0.006***

Values are represented as mean ± standard error mean (n = 5); *p < 0.05, **p < 0.01, ***p < 0.001 versus control.

DISCUSSION
In this study, cisplatin toxicity was examined at specific
doses and time intervals. The most common toxic effect
of cisplatin is acute renal failure (ARF), and its high
prevalence is increasing rapidly in developed and
developing countries and is responsible for severe
mortality and morbidity. 3, 17 Around 20% of cisplatininduced ARF cases occur in hospitalized patients, and a
third of these patients may experience renal injury
within 10 days. 3 The cisplatin doses used for this
experiment were 10,18 20,4 and 40 mg/kg,11 which were
reported to alter renal and hepatic functions. During the
whole treatment, no death and abnormal clinical signs
were observed in the experimental mice.
Proper growth in animals or humans can be assessed by
monitoring their body weight. Some researchers
considered body weight loss as a reliable sensitive
indicator for toxicity. 19-21 In our study, a reduction in
body weight was observed in the treated mice compared
with that in the control group. The cytotoxic effect of
cisplatin may hamper the eating behavior, and the renal
tubular injury may affect water reabsorption and cause
dehydration and inflammation; both of which are
responsible for the significant body weight loss. 22 Similar
results were previously reported. 18 Therefore, this
finding indicated that cisplatin potentially alters growth.
In addition to its role in growth, the effect of cisplatin on
different organ weights was studied. Cisplatin decrease
the weight of vital mouse organs such as the liver and
kidney.23
Cisplatin-induced nephrotoxicity and hepatotoxicity
remain poorly understood. For the determination of
kidney function, serum creatinine and BUN levels were
examined. High levels of these parameters were found
in the cisplatin-treated groups, especially in group 4
after 7 days of experiment. Elevated serum creatinine
and BUN are indicators of renal dysfunction. 24, 25 The
kidney is affected by cisplatin through the necrosis of
tube, the dislocation of tubular cells from the membrane
of basement, and the presence of proteinaceous casts in
the lumen of tube. 26 This drug affects the proximal and
distal convoluted tubules of kidney by inducing
apoptosis, DNA damage, and oxidative stress that
increases reactive oxygen species and inflammation. 27
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These results indicated that cisplatin is responsible for
renal dysfunction.
For hepatic activity study, the mice treated with cisplatin
showed depleted liver weight and elevated serum ALT,
the markers of liver damage. 11 In this experiment, three
doses were applied to perform the same function but in
different rates. The results indicated that cisplatin
suppressed liver function by the increasing serum ALT in
the mice, particularly in group 4 after 7 days of
observation. Comparison between groups revealed that
cisplatin caused alterations in liver parenchyma such as
hepatic lobule disorientation, hepatocyte swelling,
inflammatory cell infiltration, bile duct proliferation, and
necrotic hepatocytes.23
These data are similar to previous study. However, our
research adopted a minor modification in methods. In a
previous study, high blood urea and creatinine
concentrations were observed in the cisplatin-treated
group because of the marked depletion of creatinine
clearance compared with that in the control group. 3
Moreover, cisplatin has adverse effects on hematological
parameters such as RBCs and WBCs. Approximately 9%–
40% of patients experience cisplatin-related anemia, a wellknown side effect. One possible explanation for this
symptom is the failure to produce erythropoietin due to
ARF.28-31 Cisplatin chemotherapy can also reduce the
number of infection-fighting WBCs in the body because
the oxidative stress caused by cisplatin in lymphocytes
may hamper their life expectancy and initiate apoptosis.
As a result, the number of these cells may decrease, the
immune system may weaken, and the risk for certain
types of infection may increase. 32
On the basis of the above consideration, cisplatin should
be used carefully because of its dose-dependent toxicity.
The results of this study are important because of the
dose variation outcome of study parameters. Despite its
importance, this work has some limitations.
Interventions on the study parameters by nutritional
supplements or other medications that are used along
with cisplatin were not considered. Future research may
focus on determining whether nutritional supplement or
other medication changes the study parameters.
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22.370 ± 0.451**

30.417 ± 0.485

25.327 ± 0.548**

Group 2
(10 mg/kg body)

Group 3
(20 mg/kg body)

Group 4
(40 mg/kg body)

271.413 ± 0.560***

193.537 ± 0.462***

123.120 ± 0.400***

21.760 ± 0.291

72 h

167.793±1.226***

95.287 ± 0.294***

83.087 ± 0.216***

24.910 ± 0.447

1 week

7.843 ± 0.075**

7.577 ± 0.038***

8.450 ± 0.281

8.247 ± 0.009

6h

3.367 ± 0.088***

5.200 ± 0.058***

6.300 ± 0.058***

8.207 ± 0.035

72 h

RBC (millions/cmm)

1 week

5.627 ± 0.058***

6.290 ± 0.021***

7.647 ± 0.037***

8.203 ± 0.008

Values are represented as mean ± standard error mean (n = 5); * p < 0.05, **p < 0.01, ***p < 0.001 versus control.

18.230 ± 0.302

6h

Group 1
(Control)

Treatment

SGPT (U/L)

TABLE 6. Effect of cisplatin on SGPT, RBC, and WBC

8.283 ± 0.059***

7.567 ± 0.240

8.200 ± 0.058***

7.267± 0.088

6h

3.300 ± 0.208***

5.167 ± 0.176***

6.600 ± 0.058***

8.300 ± 0.058

72 h

WBC (T/cmm)

5.567 ± 0.046***

6.340 ± 0.133***

7.597 ± 0.032***

8.567 ± 0.033

1 week
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CONCLUSIONS
Cisplatin chemotherapy causes many problems in the
physiological and biochemical parameters on mice
particularly at high doses. Long-term observation also
supported this result. Although cisplatin is a wellestablished chemotherapy drug and is extremely
effective, it should be used carefully and cautiously for
cancer treatment.
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